1. Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018;391:2335–45. https://doi.org/10.1016/S0140-6736(18)31082-1; PMID: 29803590.
2. Bohm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet 2020;395:1444–51. https://doi.org/10.1016/S0140-6736(20)30554-7; PMID: 32234534.
3. Kandzari DE, Bohm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 2018;391:2346–55. https://doi.org/10.1016/S0140-6736(18)30951-6; PMID: 29803589.
4. Mahfoud F, Kandazari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet 2022;399:1401–10. https://doi.org/10.1016/S0140-6736(22)00455-X; PMID: 35390320.
5. Azizi M, Sanghvi K, Saxena M, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN Trio): a randomised, multicentre, single-blind, sham-controlled trial. Lancet 2021;397:2476–86. https://doi.org/10.1016/S0140-6736(21)00788-1; PMID: 34010611.